Backed by world-renowned partners and investors
PULSENSE
®
SENSING
EVERY
HEARTBEAT
1
1
PAP Sensor Insert
PAP Sensor Insert
CONTINUAL READINGS
CONTINUAL READINGS
An outpatient procedure places a minimal sensor device.
Provides ongoing, precise pulmonary artery pressure assessments for a lifetime.
2
2
Smart Patch
Smart Patch
Smart Patch
PROACTIVE TRACKING
PROACTIVE TRACKING
An unobtrusive chest patch captures readings in real-time.
Interprets and transmits patient data, enabling seamless, remote monitoring.
3
3
AI-Powered App
AI-Powered App
ON-DEMAND INSIGHTS
ON-DEMAND INSIGHTS
A dedicated app evaluates patient information as required.
Comprehensive analytics deliver organised and actionable insights for clinicians.
The Science Behind ContinuAL Monitoring
The Science
Behind ContinuAL Monitoring
Studies show how PAP fluctuations expose the limits of current systems, proving the need for consistent monitoring
Capturing PAP Daily Patterns
Spot checks miss daily fluctuations and age-specific differences, making continuous monitoring a more accurate approach than mean or maximum values.
Capturing PAP Daily Patterns
Spot checks miss daily fluctuations and age-specific differences, making continuous monitoring a more accurate approach than mean or maximum values.
Addressing Nighttime Risks
A critical change in PAP occurs between 3 and 8 AM, a high-risk period that's often missed by standard spot measurements.
Addressing Nighttime Risks
A critical change in PAP occurs between 3 and 8 AM, a high-risk period that's often missed by standard spot measurements.
Understanding Activity Impact
PAP also rises sharply during physical activity, revealing risks tied to exertion that static measurements during rest can’t detect.
Understanding Activity Impact
PAP also rises sharply during physical activity, revealing risks tied to exertion that static measurements during rest can’t detect.
Delivering Personalised Care
HFrEF and HFpEF patients have different PAP patterns.
Continual monitoring prevents heart damage and enables patient-specific symptom management.
Delivering Personalised Care
HFrEF and HFpEF patients have different PAP patterns. Continual monitoring prevents heart damage and enables patient-specific symptom management.
PRECISION CARDIOVASCULAR
precision
cardiovascular
PCV PULSENSE® is an investigational device and is not yet approved for commercial sale. It is currently undergoing regulatory review and clinical evaluation to ensure safety and efficacy. The device is limited by federal law to investigational use only and has not been cleared or approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the U.S. Food and Drug Administration (FDA), or the European Medicines Agency (EMA).
PCV PULSENSE® is an investigational device and is not yet approved for commercial sale. It is currently undergoing regulatory review and clinical evaluation to ensure safety and efficacy. The device is limited by federal law to investigational use only and has not been cleared or approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the U.S. Food and Drug Administration (FDA), or the European Medicines Agency (EMA).
Company registered in England & Wales, No. 13366126 | The Magdi Yacoub Institute, Harefield Hospital, Harefield, Uxbridge UB9 6JH
Company registered in England & Wales, No. 13366126 | The Magdi Yacoub Institute, Harefield Hospital, Harefield, Uxbridge UB9 6JH
Company registered in England & Wales, No. 13366126 | The Magdi Yacoub Institute, Harefield Hospital, Harefield, Uxbridge UB9 6JH